Xolair improves patients' asthma-related quality of life

Published: 2010-06-21 06:57:00

Updated: 2010-06-21 06:57:00

Results of a clinical study presented at a local congress of the Korean Academy of Asthma, Allergy and Clinical Immunology show that Xolair (omalizumab) reduced the rate of severe asthma exacerbations in patients with inadequately controlled severe persistent asthma, who are at high risk of life-...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK